ICC award looms in US-Chinese biotech dispute

A US biotech company and its Chinese partner are awaiting an ICC award in a US$200 million-plus dispute over a collaboration to develop cancer-fighting antibodies.

Unlock unlimited access to all Global Arbitration Review content